Expert Interviews
Jonathan Thompson, MD, MS, on the Impact of the Phase 2 BGBC008 Study Results
February 8th 2021The ongoing phase 2 BGBC008 trial demonstrated that combination treatment with bemcentinib and pembrolizumab was well tolerated and clinically active in patients with checkpoint inhibitor (CPI)–naïve and CPI-refractory composite AXL-positive non–small cell lung cancer.
Kelley Lauren Coffman, MD, on a Study of 177Lu-DOTATATE in Well-Differentiated, High-Grade NETs
February 3rd 2021The hospitalist at Memorial Sloan Kettering Cancer Center highlighted important takeaways from a study which evaluated the use of 177Lu-DOTATATE in patients with well-differentiated, high-grade neuroendocrine tumors.
Jonathan Thompson, MD, MS, on the Results of the Phase 2 BFBC008 Trial for Advanced NSCLC
February 2nd 2021According to trial investigators, the results of the ongoing BFBC008 study point support the continued development of AXL inhibition with bemcentinib in order to extend the efficacy of immunotherapy in biomarker-selected refractory non–small cell lung cancer.
Quoc-Dien Trinh, MD, on Declines in Cancer & Precancer Diagnoses During COVID-19 Pandemic
February 2nd 2021The urologist at Dana-Farber Cancer Institute/Brigham and Women’s Cancer Center spoke about the impact of a decline in cancer screening tests being performed during the first wave of the pandemic.
Lauren Averett Byers, MD, on the Identification of SCLC Subtypes
January 29th 2021The associate professor of Thoracic/Head & Neck Medical Oncology at The University of Texas MD Anderson Cancer Center indicated that these data provide the first avenue for personalized treatment of small cell lung cancer.
